| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TVJL.2015.06.015 |
| P698 | PubMed publication ID | 26526523 |
| P50 | author | Robert Klopfleisch | Q42203407 |
| P2093 | author name string | B Kohn | |
| A D Gruber | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells | Q46817260 | ||
| Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. | Q51773044 | ||
| Widespread mismatch repair protein expression in canine cutaneous mast cell tumors. | Q51786404 | ||
| Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma. | Q54193708 | ||
| Prognostic significance of the expression levels of the p16, p15, and p14 genes in dogs with high-grade lymphoma. | Q54230653 | ||
| Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. | Q54377554 | ||
| Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. | Q54465322 | ||
| Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. | Q55043363 | ||
| Positive association between a glutathione-S-transferase polymorphism and lymphoma in dogs | Q57441372 | ||
| Expression of a multidrug resistance gene in human cancers | Q69366790 | ||
| BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables | Q73592738 | ||
| Metallothionein expression in canine and feline mammary and melanotic tumours | Q74571516 | ||
| Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma | Q80557198 | ||
| Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance | Q81308407 | ||
| Metallothionein expression in benign and malignant canine mammary gland tumours | Q81483091 | ||
| Widespread mismatch repair expression in feline small intestinal lymphomas | Q82036834 | ||
| Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma | Q82568439 | ||
| Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome | Q83262134 | ||
| Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine | Q83668556 | ||
| MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling | Q24304423 | ||
| Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia | Q24310753 | ||
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| Reaction of human metallothionein-3 with cisplatin and transplatin | Q24338731 | ||
| Chromatin: constructing the big picture | Q24632812 | ||
| CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts | Q24642170 | ||
| Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment | Q24656967 | ||
| Cancer stem cells--important players in tumor therapy resistance | Q26823015 | ||
| Trials with 'epigenetic' drugs: an update | Q27000542 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Glioma stem cells promote radioresistance by preferential activation of the DNA damage response | Q27860541 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors | Q28279114 | ||
| Exploring the role of cancer stem cells in radioresistance | Q28282037 | ||
| The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas | Q28299374 | ||
| Molecular carcinogenesis of canine mammary tumors: news from an old disease | Q28300581 | ||
| Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas | Q28307817 | ||
| DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study | Q28534784 | ||
| Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo | Q28572747 | ||
| Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM | Q28611443 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 | Q33521938 | ||
| Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo | Q33720256 | ||
| Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. | Q33726782 | ||
| Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity | Q33915063 | ||
| Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors? | Q34010120 | ||
| Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia | Q34157874 | ||
| Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes | Q34322014 | ||
| Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines | Q34407959 | ||
| Drug resistance in cancer: an overview. | Q34437369 | ||
| The evolving cancer stem cell paradigm: implications in veterinary oncology | Q34460364 | ||
| Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia | Q34536382 | ||
| Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells. | Q34774983 | ||
| Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance | Q34996744 | ||
| Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks | Q35001086 | ||
| DNA damage response and DNA repair - dog as a model? | Q35123713 | ||
| IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells | Q35141573 | ||
| Molecular mechanisms of resistance and toxicity associated with platinating agents | Q35758048 | ||
| Tumoral drug metabolism: overview and its implications for cancer therapy | Q35996426 | ||
| Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein | Q36296183 | ||
| Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development | Q36430196 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| Mechanisms of chemoresistance to alkylating agents in malignant glioma | Q36726010 | ||
| Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway | Q36967531 | ||
| 5-Fluorouracil: mechanisms of resistance and reversal strategies | Q37270356 | ||
| A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition | Q37670967 | ||
| A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. | Q37711644 | ||
| Targeting Wnt signaling: can we safely eradicate cancer stem cells? | Q37763415 | ||
| Towards novel paradigms for cancer therapy. | Q37799251 | ||
| Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression | Q37849716 | ||
| Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells | Q37878174 | ||
| Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance | Q37987293 | ||
| DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. | Q38025707 | ||
| The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance | Q38037329 | ||
| Kinase dysfunction and kinase inhibitors | Q38075152 | ||
| Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug | Q38083793 | ||
| ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. | Q38107993 | ||
| Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. | Q38187646 | ||
| Poised epigenetic states and acquired drug resistance in cancer | Q38254072 | ||
| The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade | Q38305824 | ||
| Personalised medicine in veterinary oncology: one to cure just one. | Q38340264 | ||
| Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma | Q38397528 | ||
| The regulation of the expression of ABCG2 gene through mitogen-activated protein kinase pathways in canine lymphoid tumor cell lines | Q38696906 | ||
| Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR | Q38752082 | ||
| Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation | Q38909315 | ||
| Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines | Q38915906 | ||
| Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma | Q38979920 | ||
| Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines | Q38989693 | ||
| Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells | Q38996410 | ||
| Canine mammary carcinoma cell line are resistant to chemosensitizers: verapamil and cyclosporin A. | Q39005191 | ||
| Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients | Q39044254 | ||
| Expression of asparagine synthetase predicts in vitro response to L-asparaginase in canine lymphoid cell lines | Q39096462 | ||
| CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer | Q39123011 | ||
| Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein | Q39202090 | ||
| Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus | Q39215473 | ||
| Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells | Q39264734 | ||
| Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. | Q39368008 | ||
| DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency | Q39815141 | ||
| Expression of Multidrug Resistance-Associated P-Glycoprotein in Feline Tumours | Q39832673 | ||
| Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78. | Q39839037 | ||
| Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. | Q39996225 | ||
| Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells | Q39996238 | ||
| ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis | Q40131845 | ||
| Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines | Q40162939 | ||
| Molecular analysis of multidrug resistance in feline lymphoma cells | Q40856325 | ||
| A longitudinal study of ABC transporter expression in canine multicentric lymphoma | Q41727264 | ||
| Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells | Q42040567 | ||
| Targeting colorectal cancer stem cells with inducible caspase-9 | Q42116107 | ||
| Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death | Q42441668 | ||
| Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy | Q43074794 | ||
| Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma | Q44701589 | ||
| BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling | Q45065876 | ||
| Increased expression of the antiapoptotic protein MCL1 in canine mast cell tumors | Q45146096 | ||
| Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. | Q46469047 | ||
| Xenobiotic-metabolizing enzymes in canine mammary tumours | Q46598355 | ||
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 63-72 | |
| P577 | publication date | 2015-07-06 | |
| P1433 | published in | The Veterinary Journal | Q15752615 |
| P1476 | title | Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology | |
| P478 | volume | 207 |
| Q36264911 | Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy |
| Q90303961 | Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis |
| Q36926967 | Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance |
| Q38828353 | Mechanisms of tumor cell resistance to the current targeted-therapy agents. |
| Q42658274 | The Different Mechanisms of Cancer Drug Resistance: A Brief Review. |
Search more.